Understanding Tysabri and PML: What Ohio Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health to Specific Risk: The Tysabri Context

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection can have devastating long-term effects. Building on decades of public health communication that empowers patients to ask informed questions, this page provides clear, factual information about Tysabri-associated PML, including risk factors, symptoms, and what the latest research says about long-term outlook.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed in the prescribing information to alert healthcare professionals and patients to the serious nature of this adverse event. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors 'should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism, Diagnosis, and Clinical Presentation of PML

The mechanism linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri blocks alpha-4 integrins, preventing lymphocytes from crossing the blood-brain barrier. This reduces immune activity in the central nervous system, allowing latent JC virus to reactivate and cause PML. Clinical presentation of PML typically includes progressive neurological deficits such as weakness, cognitive decline, vision loss, and coordination problems. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The FDA advises that healthcare professionals 'should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML' and that 'TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these recommendations, PML can progress rapidly, leading to severe disability or death. The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The boxed warning and detailed risk information in the prescribing information are intended to inform prescribers and patients. However, questions may arise about whether these warnings were sufficiently communicated or understood in individual cases.

Statute of Limitations for Tysabri Claims in Ohio

For Ohio residents considering legal action related to Tysabri-associated PML, the statute of limitations is a key factor. In Ohio, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule means the clock starts when the patient or their representative becomes aware of the link between Tysabri and PML. For PML, this could be at the time of diagnosis or when medical records confirm the connection. Given the progressive nature of PML, early consultation with an attorney is advisable to preserve legal rights. Attorney-related considerations for affected patients include gathering medical records, documenting the timeline of Tysabri use and PML diagnosis, and assessing whether the prescribing physician adequately warned about PML risk. Legal claims may focus on failure to warn, inadequate monitoring, or product liability. The restricted distribution program for Tysabri, called the TOUCH Prescribing Program, is designed to manage risk but does not eliminate the possibility of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adverse Event Reporting and Risk Context

The FDA's adverse event reporting system (FAERS) lists fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported adverse events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most common reports, its severity makes it a critical concern. For patients who developed PML, the timeline between exposure and documented harm is important. PML can occur months to years after starting Tysabri, with risk increasing after two years of treatment. In summary, Tysabri carries a known risk of PML, with specific factors increasing that risk. For Ohio patients who have developed PML, the statute of limitations typically allows two years from discovery of the injury. Prompt legal and medical evaluation is essential to address both health needs and potential legal claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Ohio?

In Ohio, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For PML, this typically starts at diagnosis or when the link to Tysabri is confirmed.

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are the presence of anti-JCV antibodies, treatment duration beyond two years, and prior use of immunosuppressants. These factors are outlined in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.